Tradestie Institutional Equity Comparison Engine

HRMY vs AKRO โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

HRMY Overall Edge

HRMY Captures Institutional Edge (3โ€“1 Pillars ยท 7โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Harmony Biosciences Holdings, Inc. Common Stock (HRMY) driven by superior Valuation, Growth & Margin, Options & Structure while AKRO counters with relative strength in Momentum & Technical. Fundamentally, HRMY trades at 5.4x Forward P/E with 22.2% operating margin (+12.3% YoY revenue) versus AKRO at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, HRMY sits in CONSOLIDATION (11th %ile IV; Dealer Gamma Walls on Pro) against AKRO sits in UNCLASSIFIED (30th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner HRMY
HRMY 5.4x vs AKRO N/M Fwd P/E
Growth & Margin Winner HRMY
Op Margin 22.2% vs 0.0% ยท YoY +12.3% vs +0.0%
Momentum & Technical Winner AKRO
1Y -2.2% vs +76.8% ยท 52W Pos 38% vs 90%
Options & Structure Winner HRMY
CONSOLIDATION (11th %ile IV) vs UNCLASSIFIED (30th %ile IV)
HRMY NASDAQ
Harmony Biosciences Holdings, Inc. Common Stock
Pharmaceutical Preparations
$32.59
-1.18% 1D
Market Cap $1.9B
1M Return -9.55%
1Y Return -2.16%
Forward P/E 5.4x
Unified AI Score
67.1 / 100 BUY
Tech 80.0 Fund 74.0 Flow 70.0 Mom 70.0
AKRO NASDAQ
Akero Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$54.65
+0.32% 1D
Market Cap $4.5B
1M Return +1.37%
1Y Return +76.75%
Forward P/E N/M
Unified AI Score
60.0 / 100 BUY
Tech 55.0 Fund 52.0 Flow 50.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: HRMY -2.16% AKRO +76.75% Spread: +16.27 pp (HRMY Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
HRMY TTM Op. Margin: 22.2% AKRO TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on HRMY vs AKRO. Trailing 12-month operating profitability (HRMY 22.2% vs AKRO 0.0%) and valuation multiples (HRMY 5.4x vs AKRO N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: HRMY (7) vs AKRO (3)
Institutional Metric HRMY AKRO Criterion Row Winner
Market Capitalization Scale $1.9B $4.5B Larger Scale AKRO
Trailing P/E Ratio Valuation 10.9x N/M Lower Multiple HRMY
Forward P/E Ratio Valuation 5.4x N/M Lower Multiple HRMY
Revenue Growth (YoY) Growth +12.3% +0.0% Higher Growth HRMY
Operating Margin (TTM) Profitability 22.2% 0.0% Higher Margin HRMY
Net Profit Margin Profitability 18.1% 0.0% Higher Margin HRMY
Return on Equity (ROE) Capital Efficiency 18.7% -34.5% Higher ROE HRMY
52-Week Range Position Momentum 38% ($26โ€“$43) 90% ($21โ€“$58) Stronger Trend AKRO
Beta / 30D Volatility Risk Regime 0.55ฮฒ ยท 38% Vol 0.90ฮฒ ยท 2% Vol Lower Realized Risk AKRO
Unified Institutional Score Composite Signal 67.1 / 100 (BUY) 60.0 / 100 (BUY) Higher Composite HRMY

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full HRMY vs AKRO Buy Guide
HRMY CONSOLIDATION
114d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 11th %ile
IV Regime Compressed (<25th %ile)
Live HRMY Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
AKRO UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 30th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live AKRO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither HRMY nor AKRO registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.